13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05154370 (ClinicalTrials.gov) | December 15, 2021 | 8/11/2021 | China National Registry of CNS Inflammatory Demyelinating Diseases | China National Registry of Central Nervous System Inflammatory Demyelinating Diseases: a Prospective Cohort Study | Multiple Sclerosis;NMO Spectrum Disorder;Clinically Isolated Syndrome;CNS Demyelinating Autoimmune Diseases;Acute Disseminated Encephalomyelitis | Drug: Intravenous steroid | Beijing Tiantan Hospital | NULL | Recruiting | N/A | N/A | All | 10000 | China | |
| 2 | NCT01411514 (ClinicalTrials.gov) | August 2011 | 26/5/2011 | Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis | Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort | Multiple Sclerosis | Drug: Prednisone;Drug: Placebo | Claudio Gobbi | Ente Ospedaliero Cantonale, Ticino, Switzerland | Terminated | 18 Years | 80 Years | Both | 27 | Phase 4 | Switzerland |